文献速递慢性静脉疾病

法国大隐静脉与小隐静脉治疗后30天再住院全国观察研究

Thirty-day rehospitalization after saphenous vein treatment in France: A nationwide observational study.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-08-31

结果显示小隐静脉治疗后30天再住院率为1.2%,大隐静脉为4.3%,血栓栓塞、大出血和感染再住院极罕见;大隐静脉手术较腔内热消融再住院风险更低(aOR 0.54,95%CI 0.41-0.71)。

要点

  • 小隐静脉治疗后30天再住院率1.2%,大隐静脉为4.3%。
  • 血栓栓塞再住院极罕见:小隐静脉0.01%,大隐静脉0.03%。
  • 大隐静脉手术再住院风险低于腔内热消融(aOR 0.54)。

核心结论

  • 法国全国队列中,大隐静脉和小隐静脉干预后30天再住院不常见,需再住院的严重并发症极罕见。
  • 腔内热消融是主要治疗方式且安全性良好,再住院主要受患者特征而非手术相关重大并发症影响。

研究设计与样本

  • 基于法国国家健康数据系统的全国性观察研究。

主要发现

  • 腔内热消融占小隐静脉干预的77.3%、大隐静脉干预的83.4%。
  • 30天全因再住院率:小隐静脉治疗后1.2%,大隐静脉治疗后4.3%。
  • 血栓栓塞再住院率:小隐静脉治疗后0.01%,大隐静脉治疗后0.03%;大出血和感染并发症几乎不存在。
  • 小隐静脉干预中,校正后治疗方式与再住院无独立关联。
  • 大隐静脉干预中,手术较腔内热消融的30天再住院风险更低(aOR 0.54,95%CI 0.41-0.71);腔内激光与射频消融间无差异(aOR 0.97,95%CI 0.81-1.16)。

临床怎么用

  • 大隐静脉或小隐静脉功能不全行腔内热消融后30天严重并发症再住院风险极低,可据此向患者说明安全性。
  • 对大隐静脉干预,若关注再住院风险,可结合患者特征权衡手术与腔内热消融的选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Endovenous thermal ablation (EVTA) has become increasingly used for treatment of saphenous vein incompetence. However, severe adverse events leading to rehospitalization remain insufficiently characterized in large real-world populations. This study aimed to evaluate 30-day rehospitalization after great saphenous vein (GSV) and small saphenous vein (SSV) interventions in France and compare outcomes between EVTA and surgery. METHODS: We conducted a nationwide observational study using the French National Health Data System (Système National des Données de Santé). Adult patients undergoing GSV or SSV intervention between January 2020 and November 2024 were identified using International Classification of Diseases, 10th Revision and Common Classification of Medical Acts. The primary outcome was all-cause 30-day rehospitalization after discharge. Secondary outcomes included rehospitalization for thromboembolic events, major bleeding, infection, and other procedure-related complications. Multivariable logistic regression analyses were performed to identify factors associated with rehospitalization. RESULTS: A total of 450,202 patients underwent saphenous vein intervention, including 65,485 SSV and 384,717 GSV procedures. EVTA represented 77.3% of SSV interventions and 83.4% of GSV interventions. Thirty-day rehospitalization occurred in 1.2% of patients after SSV treatment and 4.3% after GSV treatment. Rehospitalizations due to thromboembolic complications were exceptionally rare (0.01% after SSV treatment and 0.03% after GSV treatment), whereas major bleeding and infectious complications were nearly absent. For SSV interventions, treatment modality was not independently associated with rehospitalization after adjustment. For GSV interventions, surgery was associated with a lower risk of 30-day rehospitalization compared with EVTA (adjusted odds ratio, 0.54; 95% confidence interval, 0.41-0.71). Among patients treated with EVTA for GSV incompetence, no difference was observed between endovenous laser ablation and radiofrequency ablation (adjusted odds ratio, 0.97; 95% confidence interval, 0.81-1.16). CONCLUSIONS: In this nationwide French cohort, 30-day rehospitalization after saphenous vein intervention was uncommon, and severe complications requiring rehospitalization were exceptionally rare. EVTA was the predominant treatment modality and demonstrated an excellent safety profile. Rehospitalization appeared to be influenced primarily by patient characteristics rather than major procedure-related complications, supporting the safety of contemporary treatment strategies for both GSV and SSV incompetence.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Lareyre F, Chierici A, Gelves AA, et al. Thirty-day rehospitalization after saphenous vein treatment in France: A nationwide observational study. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42674219. doi:10.1016/j.jvsv.2026.102606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。